MKMerli Koitmäe

Merli Koitmäe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Merli Koitmäe has a total of 235 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Validation of the GastroIntestinal Dysfunction Score (GIDS): prospective observational multicentre study (GUTPHOS Study)

    by Annika Reintam Blaser, Merli Koitmäe, Arthur R. H. van Zanten, Oskar Appelberg, Yaseen M. Arabi, Varsha Asrani, Anca Balintescu, Guillaume Besch, Jonas Blixt, Giuliano Bolondi, et al.


  • Open Access

    CT-based radiological score (AMESI CT-score) for severity of bowel injury in acute mesenteric ischemia

    by Martin Reim, Merli Koitmäe, Miklosh Bala, Alan Biloslavo, Dumitru Casian, Andee Dzulkarnaen Zakaria, Hanne Fuglseth, Moritz Geck, Lorenzo Gibello, Moran Hellerman Itzhaki, et al.


  • Open Access

    Potential time-sensitive biomarkers for the detection of acute mesenteric ischaemia: a systematic review of animal data

    by Alastair Forbes, Kaspar F. Bachmann, Karri Kase, Ele Kiisk, Kaja-Triin Laisaar, Vladislav Mihnovits, Marko Murruste, Merli Koitmäe, Joel Starkopf, Kadri Tamme, et al.

    Acute mesenteric ischemia (AMI) is difficult to recognize and is often diagnosed late. Currently there are no established biomarkers that can assist in diagnosis or management. The present study was a systematic review of animal data, intended to identify potentially time-sensitive biomarkers for human AMI. A systematic literature search was conducted using PubMed, Web of Science, and Scopus up to 10/02/25. Studies assessing potential biomarkers of AMI in mammalian models, with timed responses from the onset of experimental ischemia were selected. Data quality was assessed using CAMARADES, and PRISMA guidelines were followed. Searches identified 2175 publications from which 342 were selected for full text review, and 61 papers describing 103 experiments on 53 potential biomarkers were analyzed. The models were very heterogeneous and a meaningful meta-analysis was not possible for any biomarker. However, a pragmatic list of biomarkers of potential value in AMI that could warrant investigation in humans has been formulated. Those proposed are D-lactate, intestinal fatty acid-binding protein, ischaemia-modified albumin, and signal peptide-CUB-EGF domain-containing protein 1. No single biomarker has provided unambiguous evidence to promote its use in clinical practice, but several may deserve further evaluation in future human studies.Study funding: Estonian Research Council, Grant PRG 1255.Study registration: PROSPERO CRD42023400888 (reference 400888).


  • Open Access

    Polygenic Risk Links to the Gut Microbiome: The MAGI Catalog

    by Oliver Aasmets, Jelisaveta Dzigurski, Nele Taba, Merli Koitmae, Estonian Biobank Research Team, Triin Laisk, Elin Org, Reedik Magi, Kristi Lall

    Polygenic risk scores (PRSs) can effectively identify individuals at risk across various health conditions, yet their association with the gut microbiome remains uncharacterized. We systematically analyzed associations between 4,794 PRSs covering 615 traits and diseases and the gut microbiome within the Estonian Microbiome Cohort (N > 2,500). Microbiome diversity was associated with 62 distinct PRSs across 10 traits, indicating that genetic predisposition is linked to significant alterations in the microbiome composition. At the species level, 282 associations were identified across 100 PRSs for 34 traits, with triglyceride measurements, glucose regulation, and chronotype measurement PRSs showing the strongest signals. Mediation analysis suggests that the microbiome is altered by physiological changes linked to genetic risk but can also mediate this risk. These results help define early microbial biomarkers and explain inter-individual variability. The findings are accessible through the interactive Microbiome And Genomic Interaction (MAGI) Catalog to support future research.

  • Open Access

    Clinical Characteristics and Outcomes of Non-occlusive Mesenteric Ischemia: A Substudy of a Prospective Multicenter Observational Cohort

    by Vladislav Mihnovitš, Merli Koitmäe, Kadri Tamme, Martin Björck, Stefan Acosta, Miklosh Bala, Alain Biloslavo, Zsolt Bodnar, Dumitru Casian, Darja Clinch, et al.

    BackgroundNon-occlusive mesenteric ischemia (NOMI) remains poorly described and defined in the literature. This study aims to describe the clinical profile, risk factors, diagnostics, management, and outcomes of NOMI patients within the prospective multicenter AMESI cohort.MethodsPatients with NOMI were compared to patients with other subtypes of AMI, and patients with suspected but not confirmed AMI.ResultsNOMI patients (n=55) had a median age of 70, and 61.8% were male. At diagnosis, NOMI patients were more critically ill than other AMI (231 arterial, 73 venous, 48 with an unclear mechanism) or no AMI (n=159) patients, with median SOFA and APACHE II scores of 11 and 25, respectively. Shock at the time of suspicion (54.5%) was the most common initial sign. Although median lactate levels were elevated (4.3 mmol/L), 25.4% had normal lactate at diagnosis. Despite being used as a first-line diagnostic tool in 83.6% of NOMI cases, CT confirmed the diagnosis in only 52.7%. In-hospital mortality was 72.7%, the highest among subtypes of AMI. History of myocardial infarction, vasopressor use, and raised creatinine at the time of suspicion predicted NOMI. Bowel necrosis predicted mortality and ongoing antiplatelet therapy was associated with survival. AMI Patients with an unclear mechanism resembled NOMI in comorbidity burden and mortality, despite having a less severe illness.ConclusionsCompared with other AMI subtypes, NOMI patients were more critically ill. CT confirmed the diagnosis in only half of the cases. Difficulties in diagnosis likely contributed to missed cases and persistently poor outcomes observed in NOMI patients.

  • Open Access

    Disentangling Type 2 Diabetes Risk and Comorbidity Using Genomic Structural Equation Modeling

    by Merli Koitmäe, Kristi Läll, Märt Möls, Andrew P. Morris, Krista Fischer, Reedik Mägi

    Type 2 diabetes (T2D) is a genetically and clinically heterogeneous disorder influenced by metabolic, lifestyle, and cardiometabolic factors. Understanding the shared and distinct genetic architecture underlying T2D and its upstream risk traits is critical for improved risk prediction and stratified intervention. We applied genomic structural equation modeling (SEM) to genome-wide association study (GWAS) summary statistics for eight T2D-related phenotypes: gestational diabetes, hypertension, glycated hemoglobin, fasting glucose, fasting insulin, insulin sensitivity, body mass index, and waist-to-hip ratio. Exploratory and confirmatory factor analyses identified three latent genetic factors representing glycemic regulation, insulin resistance and cardiometabolic risk, and obesity and lifestyle-related traits. Polygenic scores (PGSs) derived from multivariate GWAS of these latent factors predicted incident T2D in the Estonian Biobank, capturing overlapping yet distinct risk profiles compared with conventional metabolic PGSs. Phenome-wide and comorbidity analyses revealed that each latent factor PGS associated with specific T2D-related complications and provided broader or distinct associations compared with conventional metabolic PGSs, with the obesity and lifestyle-related factor showing the widest impact. These findings illustrate how multivariate genetic approaches can disentangle the biological heterogeneity of T2D, refine polygenic risk prediction, and reveal mechanistic pathways driving divergent patterns of disease and comorbidity.

  • Open Access

    Comparison between endovascular and surgical treatment of acute arterial occlusive mesenteric ischemia

    by Karri Kase, Annika Reintam Blaser, Merli Koitmäe, Peep Talving, Kadri Tamme, Stefan Acosta, Martin Björck, Miklosh Bala, Zsolt Bodnar, Martin Cahenzli, et al.

    The optimal strategy for initial treatment of acute occlusion of superior mesenteric artery (SMA) is debated. The aim of the study was to compare the effectiveness, timelines and outcomes of endovascular versus open surgical treatment in patients with acute SMA occlusion. This was a preplanned substudy of the prospective observational multicenter AMESI (Acute MESenteric Ischaemia) study. Patients with SMA occlusion were divided into surgical and endovascular treatment groups. The surgical group included patients initially subjected to open surgical treatment with surgical or hybrid revascularization or intestinal resection only. The endovascular group included patients initially revascularized endovascularly and was further divided according to treatment effectiveness. Patients were also categorized according to revascularization or no revascularization, and subanalysis performed for different revascularization methods. Baseline and outcome comparisons were made using Fisher and Mann–Whitney U tests. Risk-factors for in-hospital mortality were analysed using a logistic regression model. Of 158 patients 107 had surgical and 51 endovascular treatment. The surgical group had higher baseline illness severity scores, higher C-reactive protein and lactate values. The mortality in the endovascular effective, endovascular insufficient as monotherapy and surgical groups was 2.9%, 41.2% and 45.8%, respectively. In multivariable analysis surgery was not an independent risk factor for in-hospital mortality. The rate of arterial embolism was higher in the endovascular revascularization as monotherapy insufficient treatment group (10/17) compared to the endovascular revascularization as monotherapy effective (5/34) and surgical (27/107) groups. We could not identify useful best thresholds for discriminating between effective and insufficient endovascular treatment. Analysis comparing the effect of any revascularization versus no revascularization on in-hospital mortality did not show a clear benefit of revascularization and the method of revascularization did not independently influence mortality. The beneficial effect of endovascular compared to surgical treatment in unadjusted analyses is largely explained by selection of patients. None of the compared management approaches had an independent effect on mortality. The choice between endovascular and surgical treatment should not be based solely on the time elapsed from symptom onset but rather on the patient’s general condition and possibly on the cause of SMA occlusion.


  • Open Access

    Radiological diagnosis of acute mesenteric ischemia in adult patients: a systematic review and meta-analysis

    by Annika Reintam Blaser, Merli Koitmäe, Kaja-Triin Laisaar, Alastair Forbes, Karri Kase, Ele Kiisk, Marko Murruste, Martin Reim, Joel Starkopf, Kadri Tamme

    Computed tomography (CT) is widely used in diagnosing acute mesenteric ischemia (AMI), but robust identification of distinctive subtypes and stages of progression is lacking. Systematic literature search in PubMed, Cochrane Library, Web of Science and Scopus was conducted in May 2024. Studies including at least 10 adult patients and reporting radiological diagnosis of AMI versus no AMI or transmural ischemia versus no transmural ischemia were included. Meta-analyses on sensitivity and specificity of different radiological features in diagnosing AMI were conducted. From 2628 titles, 490 studies underwent full text review, and 81 were included in 14 meta-analyses. Diagnostic accuracy of CT angiography (CTA) was high - sensitivity of 92.0% and specificity of 98.8% (I2 45% and 79%, respectively), but lower for other CT protocols (sensitivity 75.8 and specificity 90.5; I2 83%). In most included studies, distinction of subtypes and severity of AMI (non-transmural or transmural) was not possible. Amongst the non-vascular features, absent/reduced bowel wall enhancement provided the best prognostic value (sensitivity 57.9 and specificity 90.1). CTA is the method of choice for diagnosing AMI with high diagnostic accuracy. None of the non-vascular features alone is sufficiently reliable to diagnose AMI or its progression to transmural necrosis, whereas a combination of different radiological features conveys a potential.


  • Open Access

    Diagnostic Performance of Clinical and Routine Laboratory Data in Acute Mesenteric Arterial Occlusion—An International Multicenter Study

    by Yasmin Soltanzadeh-Naderi, Annika Reintam Blaser, Martin Björck, Alexandre Nuzzo, Joel Starkopf, Alastair Forbes, Marko Murruste, Kadri Tamme, Peep Talving, Anna-Liisa Voomets, et al.

    Background: There are no clinical or laboratory markers that can diagnose acute mesenteric ischemia (AMI) accurately. This study aimed to find differences in clinical and laboratory markers between arterial occlusive AMI and other acute abdominal diseases where AMI was initially suspected. Methods: This was a post hoc study of an international prospective multicenter study where data on patients with suspected AMI were collected. Independent factors associated with arterial occlusive AMI were evaluated in a multivariable logistic regression analysis. Results: The number of patients with arterial occlusive AMI was 231, consisting of thrombotic (n = 104), embolic (n = 61), and indeterminate (n = 66) occlusions. The non-AMI group included 287 patients, of whom 128 had strangulated bowel obstruction. Current smoking (odds ratio [OR] 2.56, 95% confidence interval [CI] 1.31–5.03), hypertension (OR 2.08, 95% CI 1.09–3.97), bowel emptying (OR 3.25, 95% CI 1.59–6.63), and leukocytosis (OR 1.54, 95% CI 1.14–2.08) at admission were independently associated with arterial occlusive AMI compared to the non-AMI group. Conclusions: This study found clinical and laboratory data to be associated with arterial occlusive AMI in patients with suspicion of AMI, which can possibly be of value in screening for arterial occlusive AMI at the emergency department. Further studies are needed to find more accurate diagnostic markers.


  • Top Cited Papers
    Open Access

    Incidence, diagnosis, management and outcome of acute mesenteric ischaemia: a prospective, multicentre observational study (AMESI Study)

    by Annika Reintam Blaser, Merli Mändul, Martin Björck, Stefan Acosta, Miklosh Bala, Zsolt Bodnar, Dumitru Casian, Zaza Demetrashvili, Mario D’oria, Virginia Durán Muñoz-Cruzado, et al.

    Background: The aim of this multicentre prospective observational study was to identify the incidence, patient characteristics, diagnostic pathway, management and outcome of acute mesenteric ischaemia (AMI). Methods: All adult patients with clinical suspicion of AMI admitted or transferred to 32 participating hospitals from 06.06.2022 to 05.04.2023 were included. Participants who were subsequently shown not to have AMI or had localized intestinal gangrene due to strangulating bowel obstruction had only baseline and outcome data collected. Results: AMI occurred in 0.038% of adult admissions in participating acute care hospitals worldwide. From a total of 705 included patients, 418 patients had confirmed AMI. In 69% AMI was the primary reason for admission, while in 31% AMI occurred after having been admitted with another diagnosis. Median time from onset of symptoms to hospital admission in patients admitted due to AMI was 24 h (interquartile range 9-48h) and time from admission to diagnosis was 6h (1–12 h). Occlusive arterial AMI was diagnosed in 231 (55.3%), venous in 73 (17.5%), non-occlusive (NOMI) in 55 (13.2%), other type in 11 (2.6%) and the subtype could not be classified in 48 (11.5%) patients. Surgery was the initial management in 242 (58%) patients, of which 59 (24.4%) underwent revascularization. Endovascular revascularization alone was carried out in 54 (13%), conservative treatment in 76 (18%) and palliative care in 46 (11%) patients. From patients with occlusive arterial AMI, revascularization was undertaken in 104 (45%), with 40 (38%) of them in one site admitting selected patients. Overall in-hospital and 90-day mortality of AMI was 49% and 53.3%, respectively, and among subtypes was lowest for venous AMI (13.7% and 16.4%) and highest for NOMI (72.7% and 74.5%). There was a high variability between participating sites for most variables studied. Conclusions: The overall incidence of AMI and AMI subtypes varies worldwide, and case ascertainment is challenging. Pre-hospital delay in presentation was greater than delays after arriving at hospital. Surgery without revascularization was the most common management approach. Nearly half of the patients with AMI died during their index hospitalization. Together, these findings suggest a need for greater awareness of AMI, and better guidance in diagnosis and management. Trial registration: NCT05218863 (registered 19.01.2022).